The report "Vaccine Adjuvants Market by Product (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Global Forecast to 2027", is projected to reach USD 1.6 billion by 2027 from USD 1.5 billion in 2022, at a CAGR of 1.7% during the forecast period of 2022 to 2027.

Gather more insights about the market drivers, restrains and growth of the  Vaccine Adjuvants Market

The vaccine adjuvants market is expected to grow at a CAGR of 1.7% during the forecast period. The growth of the market is projected to be driven by collaborations and partnerships among market players for the development of vaccine adjuvants, an increasing number of COVID-19 vaccines in the development pipeline, and increasing focus on immunization programs.

The adjuvant emulsions segment is expected to have the dominant share of the vaccine adjuvants market

Based on product, the global vaccine adjuvants market is segmented into adjuvant emulsions, pathogen components, saponin-based adjuvants, particulate adjuvants, and other adjuvants. the adjuvant emulsions segment accounted for largest share of the vaccine adjuvants market. The extensive use of adjuvant emulsions in COVID-19 & other infectious diseases is driving the growth of the adjuvant emulsions segment during the forecast period.

The infectious disease segment accounted for the largest share of the disease type segment in the vaccine adjuvants market

The infectious diseases segment accounted for the largest share of the market in 2021. The large share of this segment can be attributed to the increasing prevalence of infectious diseases and the rising demand for new adjuvanted vaccines.

The Asia Pacific region is the fastest-growing region of the vaccine adjuvants market

The Asia Pacific is estimated to be the fastest-growing segment of the market. The growth of the vaccine adjuvants markets of the region is drive by increasing investments in the life sciences sector and rising awareness through conferences & symposiums, and growing emphasis on strategic initiatives such as partnerships, and collaborations by biopharma and biotech companies.

Key Market Players

Key players in the vaccine adjuvants market include GSK plc (UK), Dynavax Technologies (US), Novavax (US), Agenus Inc. (US), Croda International plc (UK), Seppic (France), OZ Biosciences (US), Phibro Animal Health Corporation (US), Associated British Foods plc (UK), InvivoGen (US), Merck KGaA (Germany), CSL Limited (Australia), Vertellus (US), Allergy Therapeutics (UK), Riboxx GmbH (Germany), CaPtivatϵ Pharmaceuticals LLC (US), EuBiologics Co., Ltd. (South Korea), Pacific GeneTech Limited (US), Hawaii Biotech Inc. (US), and Vaxine Pty Ltd. (Australia).

This report categorizes the vaccine adjuvants market to forecast revenue and analyze trends in each of the following submarkets:

By Product

• Adjuvant Emulsions
• Pathogen Components
• Saponin-based adjuvants
• Particulate Adjuvants
• Other Adjuvants

By Route of Administration

• Intramuscular
• Subcutaneous
• Other Route of Administration

By Disease Type

• Infectious Diseases
• Cancer
• Others

By Application

• Research Applications
• Commercial Applications

By Application Category

• Human Vaccine Adjuvants
• Veterinary Vaccine Adjuvants

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Recent Developments

• In October 2021, Dynavax Technologies (US) entered into a fully funded collaboration with the US Department of Defense to conduct a Phase 2 clinical trial for a plague vaccine adjuvanted with CpG 1018.
• In February 2021, SK Bioscience (South Korea)and GSK plc (UK)entered into a collaboration for COVID-19 vaccine development.

Order a free sample PDF of the Vaccine Adjuvants Market Intelligence Study, published by MarketsandMarkets

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA : 1-888-600-6441

sales@marketsandmarkets.com